



# LINCOLN PHARMACEUTICALS LIMITED



Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-67778000, Fax: +91-79-6777 8062,

Website: www.lincolnpharma.com, E-Mail: info@lincolnpharma.com

## Statement of Standalone and Consolidated Un-Audited Financial Results for the Quarter Ended on 30-June-2018.

| Part-I  |   | Standalone      |                 |                 |                  | Consolidated     |                 |                  |                  | (Rs. in Lakhs) |
|---------|---|-----------------|-----------------|-----------------|------------------|------------------|-----------------|------------------|------------------|----------------|
| Sr. No. | Particulars   | Quarter Ended   |                 | Year Ended      |                  | Quarter Ended    |                 | Year Ended       |                  |                |
|         |   | 30/06/2018      | 31/03/2018      | 30/06/2017      | 31/03/2018       | 30/06/2018       | 31/03/2018      | 30/06/2017       | 31/03/2018       |                |
|         |   | Un-Audited      | Un-Audited      | Un-Audited      | Audited          | Un-Audited       | Un-Audited      | Un-Audited       | Audited          |                |
| 1       | <b>Income</b>   |                 |                 |                 |                  |                  |                 |                  |                  |                |
|         | A) Revenue From Operations  | 9,663.16        | 7,249.54        | 8,775.21        | 32,551.19        | 9,982.16         | 6,712.46        | 15,023.20        | 36,163.71        |                |
|         | B) Other Income   | 224.03          | 167.37          | 255.74          | 580.38           | 229.65           | 85.67           | 284.24           | 545.37           |                |
|         | <b>Total Income</b>   | <b>9,887.19</b> | <b>7,416.91</b> | <b>9,030.95</b> | <b>33,131.57</b> | <b>10,211.81</b> | <b>6,798.13</b> | <b>15,307.44</b> | <b>36,709.08</b> |                |
| 2       | <b>Expenses</b>   |                 |                 |                 |                  |                  |                 |                  |                  |                |
|         | A) Cost of Material Consumed  | 1,816.31        | 1,662.08        | 1,255.03        | 6,359.23         | 2,654.94         | 2,470.54        | 1,810.51         | 9,155.30         |                |
|         | B) Purchase of Stock-In-Trade                                       | 2,240.91        | 2,185.41        | 4,245.88        | 10,686.23        | 1,090.91         | 688.10          | 9,668.25         | 10,393.98        |                |
|         | C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP | 420.91          | (458.63)        | 208.92          | 70.65            | 723.29           | (656.50)        | 145.07           | (297.61)         |                |
|         | D) Excise Expenses  | Nil             | Nil             | 55.76           | 55.76            | Nil              | (21.09)         | 67.61            | 102.28           |                |
|         | E) Employee Benefits Expenses                                       | 1,269.04        | 1,011.80        | 1,050.22        | 4,750.80         | 1,352.03         | 1,146.31        | 1,117.37         | 5,114.78         |                |
|         | F) Finance Costs  | 81.87           | 111.28          | 117.43          | 426.47           | 133.26           | 93.95           | 160.79           | 541.10           |                |
|         | G) Depreciation and Amortisation Expense                            | 113.82          | 110.41          | 96.00           | 439.93           | 158.02           | 153.06          | 138.00           | 611.18           |                |
|         | H) Other Expenses   | 1,749.39        | 2,013.29        | 1,377.19        | 6,032.69         | 1,831.64         | 2,120.15        | 1,512.89         | 6,463.36         |                |
|         | <b>Total Expenses</b>   | <b>7,692.24</b> | <b>6,635.64</b> | <b>8,406.43</b> | <b>28,821.77</b> | <b>7,944.09</b>  | <b>5,994.52</b> | <b>14,620.49</b> | <b>32,084.37</b> |                |
| 3       | <b>Profit / (Loss) Before Exceptional Items &amp; Tax (1-2)</b>     | <b>2,194.96</b> | <b>781.27</b>   | <b>624.52</b>   | <b>4,309.80</b>  | <b>2,267.72</b>  | <b>803.61</b>   | <b>686.95</b>    | <b>4,624.71</b>  |                |
| 4       | Exceptional Items   | Nil             | Nil             | Nil             | Nil              | Nil              | Nil             | Nil              | Nil              |                |
| 5       | <b>Profit / (Loss) after Exceptional items but Before Tax (3-4)</b> | <b>2,194.96</b> | <b>781.27</b>   | <b>624.52</b>   | <b>4,309.80</b>  | <b>2,267.72</b>  | <b>803.61</b>   | <b>686.95</b>    | <b>4,624.71</b>  |                |
| 6       | Tax Expense   |                 |                 |                 |                  |                  |                 |                  |                  |                |
|         | A. Current Tax (Net)  | 579.63          | 59.95           | 126.17          | 958.49           | 596.29           | 75.83           | 140.15           | 1,038.47         |                |
|         | B. Deferred Tax (Net)   | 55.00           | 2.62            | 48.00           | 75.66            | 64.00            | 45.16           | 55.11            | 121.30           |                |
| 7       | <b>Profit / Loss For The Period (5-6)</b>                           | <b>1,560.33</b> | <b>718.70</b>   | <b>450.35</b>   | <b>3,275.65</b>  | <b>1,607.43</b>  | <b>682.62</b>   | <b>491.69</b>    | <b>3,464.94</b>  |                |
| 8       | Attributable to:  |                 |                 |                 |                  |                  |                 |                  |                  |                |
|         | Non-Controlling Interest  | Nil             | Nil             | Nil             | Nil              | 0.64             | (0.34)          | 0.65             | 2.79             |                |
|         | <b>Owners of the Company</b>  | <b>1,560.33</b> | <b>718.70</b>   | <b>450.35</b>   | <b>3,275.65</b>  | <b>1,606.79</b>  | <b>682.96</b>   | <b>491.04</b>    | <b>3,462.15</b>  |                |
| 9       | Other Comprehensive Income (Net Of Tax)                             | 2.29            | 13.86           | (1.55)          | 9.20             | 2.46             | 14.35           | (1.49)           | 9.87             |                |
| 10      | <b>Total Comprehensive Income For The Period (11+12)</b>            | <b>1,562.62</b> | <b>732.56</b>   | <b>448.80</b>   | <b>3,284.85</b>  | <b>1,609.25</b>  | <b>697.31</b>   | <b>489.55</b>    | <b>3,472.02</b>  |                |
| 11      | Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)          | 2,000.00        | 2,000.00        | 2,000.00        | 2,000.00         | 2,000.00         | 2,000.00        | 2,000.00         | 2,000.00         |                |
| 12      | Other Equity  |                 |                 |                 | 19,954.03        |                  |                 |                  | 20,454.44        |                |
| 13      | Earnings Per Share (of Rs. 10/- Each) (Not Annualised)              |                 |                 |                 |                  |                  |                 |                  |                  |                |
|         | (A) Basic   | 7.80            | 3.59            | 2.25            | 16.38            | 8.03             | 3.41            | 2.46             | 17.31            |                |
|         | (B) Diluted   | 7.80            | 3.59            | 2.25            | 16.38            | 8.03             | 3.41            | 2.46             | 17.31            |                |

|               |   |
|---------------|---|
| <b>Notes:</b> |   |
| 1             | The Above Results have been Reviewed By the Audit Committee and Approved By The Board of Directors at their Meeting Held on August 14, 2018.  |
| 2             | Statutory Auditors have carried out Limited Review of the Financial Results for the Quarter Ended June 30, 2018.  |
| 3             | The Figures for the Quarter Ended March 31, 2018 are balancing Figures between Audited Figures In Respect of Full Financial Year and Un-Audited Published Figures Upto The Third Quarter.       |
| 4             | The company is primarily engaged in one business segment namely Pharmaceuticals segment as determined by the chief operating decision maker in accordance with IND-AS-108, "Operating Segment". |
| 5             | Previous periods figures have been regrouped and rearranged wherever necessary.   |
| 6             | Consolidated Financial Results Includes the Results of Its Subsidiaries.  |
|               | <b>FOR LINCOLN PHARMACEUTICALS LIMITED</b>  |
|               | <b>Sd/-</b><br><b>MAHENDRA G. PATEL</b><br><b>MANAGING DIRECTOR</b><br><b>DIN: 00104706</b>   |
|               | <b>PLACE: AHMEDABAD</b><br><b>DATE: AUGUST 14, 2018</b>   |